Szerző: Paul M. Barr, MD¹ Alessandra Tedeschi, MD² Talha Munir, MD³ Peter Hillmen, MD, PhD⁴ John C Byrd, MD⁵ Paolo Ghia, MD, PhD⁶ Stephen Mulligan, MBBS, MD, FRACP, FRCPA⁷ Sandra Dai, PhD, MS⁸ Carlos Amaya-Chanaga, MD⁹ James P. Dean, MD, PhD¹⁰ Susan M. o'Brien, MD^11
1Division of Hematology/Oncology, Wilmot Cancer Institute, University of Rochester, Rochester, NY
²Department of Haematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
³Department of Haematology, Leeds Teaching Hospitals, Leeds, United Kingdom
⁴The Leeds Teaching Hospitals, St. James University Hospital, (Leeds Cancer Centre, St. James' Institute of Oncology), Leeds, United Kingdom
⁵The Ohio State University, Columbus, OH; Comprehensive Cancer Center, The Ohio State University, Columbus, OH
⁶Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy
⁷Royal North Shore Hospital, Sydney, AUS
⁸Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA
⁹Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA
¹⁰Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA
¹¹UC Irvine, Chao Family Comprehensive Cancer Center, Orange, CA